

Think Tank: Exploring Novel Trial Designs and Innovative Statistical Tools in Rare Disease Drug Development

Duke-Margolis Center for Health Policy • Washington, DC May 3, 2017

Participant List

Julie Beitz

Director, Office of Drug Evaluation III, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Scott Berry

Statistical Scientist, Berry Consultants

Doug Chapman

Director, Biostatistics, Pfizer, Inc

Yeh-Fong Chen

Mathematical Statistician, Division of Biometrics III, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Shein-Chung Chow

Professor of Biostatistics and Bioinformatics, Duke University School of Medicine

Greg Daniel

Clinical Professor, Duke Fuqua School of Business and Deputy Director, Duke-Margolis Center for Health Policy, Duke University

Billy Dunn

Director, Division of Neurology Products, U.S. Food and Drug Administration

Katherine Frank

Senior Research Assistant, Duke-Margolis Center for Health Policy, Duke University

Laura Lee Johnson

Acting Division Director, Division of Biometrics III, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Lucas Kempf

Medical Officer, Rare Disease Program, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Lisa LaVange

Director, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

James MacDougall

Statistical Consultant

Olga Marchenko

Vice President and Head of Advisory Services Analytics, QuintilesIMS

Tristan Massie

Mathematical Statistican, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Nicole Mayer-Hamblett

Associate Professor of Pediatrics and Biostatistics, University of Washington and Co-Executive Director, Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Hospital

Mark McClellan

Robert J. Margolis Professor of Business, Medicine, and Policy and Director, Duke-Margolis Center for Health Policy, Duke University

Rich Moscicki

Deputy Director for Science Operations, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Tom Permutt

Division Director, Division of Biometrics II, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration

Karen L. Price

Senior Research Advisor, Eli Lilly & Company

Dionne Price

Division Director, Division of Biometrics IV, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Michael Rabbia

Principal Statistical Scientist, Biostatistics, Roche TCRC, Inc.

Morgan Romine

Managing Associate, Duke-Margolis Center for Health Policy, Duke University

Gary Rosner

E.K. Marshall Jr. Professor of Oncology and Professor of Biostatistics, Johns Hopkins University

Estelle Russek-Cohen

Retired, Biostatistics, U.S. Food and Drug Administration

Jerald S. Schindler

Vice President, Data Science and Statistics, Alnylam Pharmaceuticals

John Scott

Deputy Director, Division of Biostatistics, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Yuan-Li Shen

Lead Mathematical Statistician, Division of Biometrics V, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Roy Tamura

Associate Professor of Biostatistics, Health Informatics Institute, University of South Florida

P.K. Tandon

Senior Vice President, Biometrics & Development Strategy, Ultragenyx

Lilly Yue

Deputy Director, Division of Biostatistics, Center for Devices and Radiological Health, U.S. Food and Drug Administration